Smith & Nephew (SNN) director Esperdy named Rentokil Initial chair-designate
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Smith & Nephew plc filed a report noting that Thérèse Esperdy, its Senior Independent Director designate, will join the Board of Rentokil Initial plc as a Non-Executive Director and Chair-designate from 1 July 2026, becoming Chair of the Board on 1 September 2026. The company also highlights that it operates in more than 100 countries with $6.2 billion in annual sales in 2025, supported by around 17,000 employees across its orthopaedics, sports medicine & ENT, and advanced wound management businesses.
Positive
- None.
Negative
- None.
Key Figures
Annual sales: $6.2 billion
Employees: 17,000 employees
Geographic reach: More than 100 countries
+2 more
5 metrics
Annual sales
$6.2 billion
Full year 2025 group sales
Employees
17,000 employees
Global workforce delivering product portfolio
Geographic reach
More than 100 countries
Operational footprint worldwide
Effective date – Rentokil NED role
1 July 2026
Esperdy appointed Non-Executive Director and Chair-designate
Effective date – Rentokil Chair role
1 September 2026
Esperdy to become Chair of Rentokil Initial Board
Key Terms
Senior Independent Director, Non-Executive Director, UK Listing Rule 6.4.9R(2), forward-looking statements, +1 more
5 terms
Senior Independent Director financial
"Thérèse Esperdy, Senior Independent Director designate, will be appointed..."
A senior independent director is an experienced, independent member of a company’s board who acts as a go‑to person for shareholders, other directors, and the chair when impartial judgment or escalation is needed. Like an independent referee or ombudsman, they provide extra oversight, help resolve disputes, ensure the board listens to investor concerns, and strengthen governance—reducing the risk that management or the chair could act without adequate challenge.
Non-Executive Director financial
"...as a Non-Executive Director and Chair-designate with effect from 1 July 2026..."
A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.
UK Listing Rule 6.4.9R(2) regulatory
"This disclosure is made in accordance with UK Listing Rule 6.4.9R(2)."
forward-looking statements regulatory
"This document may contain forward-looking statements that may or may not prove accurate."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
London Stock Exchange financial
"...Rentokil Initial plc, a company listed on the London Stock Exchange..."
A major regulated marketplace in London where stocks, bonds and other securities are bought and sold, the London Stock Exchange acts like a large, organized auction house that matches buyers and sellers and records current prices. It matters to investors because it provides liquidity and reliable price information, a platform for companies to raise capital, and rules that help protect market integrity — all of which affect portfolio value and trading opportunities.
FAQ
What did Smith & Nephew (SNN) disclose in its April 2026 Form 6-K?
Smith & Nephew disclosed that Thérèse Esperdy, its Senior Independent Director designate, will join Rentokil Initial plc’s board as Non-Executive Director and Chair-designate in July 2026, becoming Chair in September 2026, in a governance-focused update made under UK Listing Rule 6.4.9R(2).
Who is Thérèse Esperdy and what new role was announced involving Smith & Nephew?
Thérèse Esperdy is Smith & Nephew’s Senior Independent Director designate. The company reported she will be appointed to Rentokil Initial plc’s board as a Non-Executive Director and Chair-designate from 1 July 2026 and will become Chair of Rentokil’s Board on 1 September 2026.
How large is Smith & Nephew’s business according to the 2025 figures?
Smith & Nephew reported annual sales of $6.2 billion in 2025. The business operates in more than 100 countries and employs about 17,000 people across orthopaedics, sports medicine & ENT, and advanced wound management product lines worldwide.
In which markets and segments does Smith & Nephew (SNN) primarily operate?
Smith & Nephew is a global medical technology company active in more than 100 countries. Its operations focus on three main business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management, targeting repair, regeneration and replacement of soft and hard tissue.
What regulatory reference governs the Smith & Nephew director disclosure?
The disclosure about Thérèse Esperdy’s external board appointment is stated to be made in accordance with UK Listing Rule 6.4.9R(2). This indicates the update relates to required transparency around directorships for companies with securities admitted to trading in the United Kingdom.
What is Smith & Nephew’s stated corporate purpose and focus?
Smith & Nephew describes its purpose as helping restore people’s bodies and self-belief, calling this ‘Life Unlimited’. It focuses on medical technologies that repair, regenerate and replace soft and hard tissue through a portfolio spanning orthopaedics, sports medicine & ENT, and advanced wound management.